专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009067611A1 SEVEN GENE BREAST CANCER PREDICTOR 审中-公开
标题翻译：七代基因乳癌预后
公开(公告)号：WO2009067611A1
公开(公告)日：2009-05-28
申请号：PCT/US2008/084213
申请日：2008-11-20
申请人： UNIVERSITY OF SOUTH FLORIDA , H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. , YEATMAN, Timothy , CHEN, Dung-Tsa , NASIR, Aejaz
发明人： YEATMAN, Timothy , CHEN, Dung-Tsa , NASIR, Aejaz
IPC分类号： C12Q1/68 , C40B40/08
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The invention provides a molecular marker set that can be used for prognosis of breast cancer in a patient using histologically normal tissue. The invention also provides methods for evaluating prognosis of breast cancer in a patient based on a molecular molecular signature.
摘要翻译：本发明提供了可以用于使用组织学正常组织的患者乳腺癌预后的分子标记物组。本发明还提供了基于分子分子特征评估患者乳腺癌预后的方法。

2. 发明申请

WO2011094483A3 IMMUNE GENE SIGNATURES IN CANCER 审中-公开
标题翻译：免疫基因在癌症中的作用
公开(公告)号：WO2011094483A3
公开(公告)日：2011-12-22
申请号：PCT/US2011022845
申请日：2011-01-28
申请人： H LEE MOFFITT CANCER CT & RES , MULE JAMES J , COPPOLA DOMENICO , YEATMAN TIMOTHY J , LOBODA ANDREY , NEBOZHYN MICHAEL V
发明人： MULE JAMES J , COPPOLA DOMENICO , YEATMAN TIMOTHY J , LOBODA ANDREY , NEBOZHYN MICHAEL V
IPC分类号： G01N33/574 , C12Q1/68 , C40B40/08 , G01N33/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/574 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/5743
摘要： This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
摘要翻译：本发明涉及基于趋化因子，细胞毒性基因和/或树突细胞基因的肿瘤表达水平来选择治疗，治疗和预测患有癌症的受试者（例如结肠直肠癌）中的存活时间的方法。

3. 发明申请

WO2011116380A3 HYBRID MODEL FOR THE CLASSIFICATION OF CARCINOMA SUBTYPES 审中-公开
公开(公告)号：WO2011116380A3
公开(公告)日：2011-09-22
申请号：PCT/US2011/029208
申请日：2011-03-21
申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. , YEATMAN, Timothy , CENTENO, Barbara A. , BLOOM, Gregory C.
发明人： YEATMAN, Timothy , CENTENO, Barbara A. , BLOOM, Gregory C.
IPC分类号： G01N33/50 , C12Q1/68 , G01N33/574 , G06F19/18
摘要： A two-tiered classification system that can be integrated with the current algorithm used by pathologists for identification of the site of origin for 'malignancy with unknown primary' is presented. In use, morphology, immunohistochemical (IHC) studies, and microarray-based top tier gene expression classifiers first subclassify cytokeratin positive carcinomas into adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma and urothelial carcinoma. Subsequently, organ-specific IHC-markers, if available, are used in conjunction with microarray-based second tier gene expression classifiers to assign the primary site of origin to the sample. This new hybrid approach combines IHC with a hierarchy of quantitative gene expression based classifiers into an algorithmic method that can assist pathologists to further refine and support their decision making process.

4. 发明申请

WO2008011046A3 COMPUTER SYSTEMS AND METHODS FOR SELECTING SUBJECTS FOR CLINICAL TRIALS 审中-公开
标题翻译：计算机系统和选择临床试验项目的方法
公开(公告)号：WO2008011046A3
公开(公告)日：2008-10-02
申请号：PCT/US2007016239
申请日：2007-07-16
申请人： H LEE MOFFITT CANCER AND RES I , UNIV SOUTH FLORIDA , YEATMAN TIMOTHY , DALTON WILLIAM S
发明人： YEATMAN TIMOTHY , DALTON WILLIAM S
IPC分类号： G01N33/48 , G06G7/48
CPC分类号： G06Q50/24 , G06Q50/22 , G16H10/20 , G16H10/60
摘要： Computers, computer program products, and methods for identifying a plurality of subjects for a clinical trial are provided. A candidate set of molecular profiles in a stored plurality of molecular profiles are identified. Each such profile has measurements for a discriminating set of cellular constituents that match the measurements of corresponding cellular constituents in a responder set of biological samples, thereby identifying the plurality of subjects for the trial from those subjects from which the candidate set of molecular profiles were derived. Each respective molecular profile in the stored plurality of profiles has measurements of a plurality of cellular constituents from a respective biological sample in a plurality of samples obtained from a first plurality of subjects. The discriminating set of cellular constituents is identified from those cellular constituents in the plurality of cellular constituents whose measurement values discriminates between the responder and nonresponder sets of biological samples.
摘要翻译：提供了计算机，计算机程序产品和用于识别用于临床试验的多个对象的方法。鉴定存储的多个分子谱中的候选分子谱集。每个这样的简档具有与生物样本的响应者组中的相应细胞成分的测量相匹配的细胞成分鉴别组的测量结果，从而从衍生出候选分子谱的集合的那些受试者中鉴定出试验的多个受试者。存储的多个轮廓中的每个相应分子轮廓具有来自从第一组多个受试者获得的多个样本中的相应生物样品的多个细胞组分的测量。从多个细胞组分中的细胞成分鉴别细胞组分的鉴别集，其测量值区分应答者和生物样品的无应答组。

5. 发明申请

WO2005083128A2 METHODS FOR PREDICTING CANCER OUTCOME AND GENE SIGNATURES FOR USE THEREIN 审中-公开
标题翻译：预测癌症结局的方法及其使用的基因信号
公开(公告)号：WO2005083128A2
公开(公告)日：2005-09-09
申请号：PCT/US2005006201
申请日：2005-02-25
申请人： UNIV SOUTH FLORIDA , YEATMAN TIMOTHY J
发明人： YEATMAN TIMOTHY J
IPC分类号： C12Q1/68 , G06F19/20 , G06F19/24
CPC分类号： G06F19/20 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G06F19/24
摘要： The present invention pertains to specific gene signatures for cancer that are used to predict survival and novel processes for identifying such gene signatures. In one embodiment, gene signatures for human colorectal cancer are identified and outcomes are linked to the specific gene signatures using significance analysis of microarrays (SAM) and support vector machines (SVM) to provide a prognosis/survival classifier.
摘要翻译：本发明涉及用于预测存活的癌症的特异性基因特征和用于鉴定这种基因特征的新方法。在一个实施方案中，使用微阵列（SAM）和支持向量机（SVM）的显着性分析来鉴定人结肠直肠癌的基因特征，并将结果与特定基因特征相关联，以提供预后/生存分类器。

6. 发明申请

WO2009089548A3 MALIGNANCY-RISK SIGNATURE FROM HISTOLOGICALLY NORMAL BREAST TISSUE 审中-公开
标题翻译：从病理性正常乳腺组织的恶性危险标志
公开(公告)号：WO2009089548A3
公开(公告)日：2010-01-07
申请号：PCT/US2009030778
申请日：2009-01-12
申请人： H LEE MOFFITT CANCER & RES INS , UNIV SOUTH FLORIDA , CHEN DUNG-TSA , YEATMAN TIMOTHY J
发明人： CHEN DUNG-TSA , YEATMAN TIMOTHY J
IPC分类号： C12Q1/68
CPC分类号： G06F19/20 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The invention provides for malignancy-risk gene signatures that predict the risk of developing breast cancer, the recurrence of breast cancer, and/or the metastasis of breast cancer. These signatures have numerous clinical applications including assessing risk of breast cancer development following routine breast biopsy, assessing the need for adjuvant radiotherapy after lumpectomy, and determining the need for completion mastectomy following lumpectomy for the breast cancer patient and other treatment plans that are personalized for the patient.
摘要翻译：本发明提供了预测乳腺癌发展，乳腺癌复发和/或乳腺癌转移的风险的恶性肿瘤风险基因特征。这些签名具有许多临床应用，包括在常规乳腺活检后评估乳腺癌发展的风险，评估在乳房切除术后辅助放疗的需要，以及确定乳腺癌患者乳房切除术后完成乳房切除术的必要性以及其他治疗计划患者。

7. 发明申请

WO2009009662A1 METHOD OF PREDICTING NON-RESPONSE TO FIRST LINE CHEMOTHERAPY 审中-公开
标题翻译：预测对第一线化疗无反应的方法
公开(公告)号：WO2009009662A1
公开(公告)日：2009-01-15
申请号：PCT/US2008/069649
申请日：2008-07-10
申请人： UNIVERSITY OF SOUTH FLORIDA , YEATMAN, Timothy , AGRAWAL, Deepak , DAUD, Adil
发明人： YEATMAN, Timothy , AGRAWAL, Deepak , DAUD, Adil
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： G01N33/57419 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G01N27/447 , G01N2800/52
摘要： The invention provides a method for determining a prognosis of colorectal cancer in a colorectal cancer patient, comprising classifying said patient as having a good prognosis or a poor prognosis using measurements of a plurality of gene products in a cell sample taken from said patient, said gene products being respectively products of at least 1 of the genes listed in Table 1, or respective functional equivalents thereof, wherein said good prognosis predicts a positive response to standard chemotherapy regimens, and said poor prognosis predicts non-responsiveness. Provided herein, the invention includes a gene signature to predict which patients will to benefit from standard colon cancer therapy; alternatively, patients who are classified as non-responders may be more likely to benefit from a novel agent such as a Notch inhibitor.
摘要翻译：本发明提供了一种用于确定结肠直肠癌患者中结肠直肠癌预后的方法，其包括使用从所述患者取得的细胞样品中的多种基因产物的测量将所述患者分类为具有良好的预后或不良预后，所述基因产品分别是表1中列出的至少1种基因的产物或其各自的功能等同物，其中所述良好预后预示了对标准化学疗法方案的阳性反应，并且所述不良预后预测无反应性。本文提供了一种基因特征，以预测哪些患者将从标准结肠癌治疗中受益; 或者，被分类为无应答者的患者可能更有可能受益于新药，例如Notch抑制剂。

8. 发明申请

WO2005083128A3 METHODS FOR PREDICTING CANCER OUTCOME AND GENE SIGNATURES FOR USE THEREIN 审中-公开
公开(公告)号：WO2005083128A3
公开(公告)日：2005-09-09
申请号：PCT/US2005/006201
申请日：2005-02-25
申请人： UNIVERSITY OF SOUTH FLORIDA , YEATMAN, Timothy, J.
发明人： YEATMAN, Timothy, J.
IPC分类号： G06F19/00 , C12Q1/68
摘要： The present invention pertains to specific gene signatures for cancer that are used to predict survival and novel processes for identifying such gene signatures. In one embodiment, gene signatures for human colorectal cancer are identified and outcomes are linked to the specific gene signatures using significance analysis of microarrays (SAM) and support vector machines (SVM) to provide a prognosis/survival classifier.

9. 发明申请

WO2011116380A2 HYBRID MODEL FOR THE CLASSIFICATION OF CARCINOMA SUBTYPES 审中-公开
标题翻译： CARCINOMA SUBTYPES分类混合模型
公开(公告)号：WO2011116380A2
公开(公告)日：2011-09-22
申请号：PCT/US2011029208
申请日：2011-03-21
申请人： H LEE MOFFITT CANCER CT & RES , YEATMAN TIMOTHY , CENTENO BARBARA A , BLOOM GREGORY C
发明人： YEATMAN TIMOTHY , CENTENO BARBARA A , BLOOM GREGORY C
IPC分类号： G01N33/50 , C12Q1/68 , G01N33/574 , G06F19/18
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N33/574 , G01N33/57484 , G06F19/20 , G06F19/24
摘要： A two-tiered classification system that can be integrated with the current algorithm used by pathologists for identification of the site of origin for 'malignancy with unknown primary' is presented. In use, morphology, immunohistochemical (IHC) studies, and microarray-based top tier gene expression classifiers first subclassify cytokeratin positive carcinomas into adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma and urothelial carcinoma. Subsequently, organ-specific IHC-markers, if available, are used in conjunction with microarray-based second tier gene expression classifiers to assign the primary site of origin to the sample. This new hybrid approach combines IHC with a hierarchy of quantitative gene expression based classifiers into an algorithmic method that can assist pathologists to further refine and support their decision making process.
摘要翻译：提出了一种双层分类系统，可与病理学家使用的当前算法结合，用于鉴定“未知原发性恶性肿瘤”的起源部位。在使用中，形态学，免疫组化（IHC）研究和基于微阵列的顶层基因表达分类器首先将细胞角蛋白阳性癌分为腺癌，鳞状细胞癌，神经内分泌癌和尿路上皮癌。随后，器官特异性IHC标记（如果可用）与基于微阵列的第二层基因表达分类器结合使用，以将原始起始位点分配给样品。这种新的混合方法将IHC与基于定量基因表达的分类器的层次结合成一种算法方法，可以帮助病理学家进一步完善和支持他们的决策过程。

10. 发明申请

WO2008116178A8 SYSTEMS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF COLORECTAL CANCER 审中-公开
标题翻译：用于诊断和预防癌症的系统和方法
公开(公告)号：WO2008116178A8
公开(公告)日：2009-09-17
申请号：PCT/US2008057884
申请日：2008-03-21
申请人： UNIV VANDERBILT , H LEE MOFFITT CANCER CT AND RE , CINCINNATI CHILDREN S HOSPITAL , COFFEY ROBERT J , ARONOW BRUCE J , FRANKLIN JEFFREY L , YEATMAN TIMOTHY , OLESEN SANNE K H , BLOOM GREGORY
发明人： COFFEY ROBERT J , ARONOW BRUCE J , FRANKLIN JEFFREY L , YEATMAN TIMOTHY , OLESEN SANNE K H , BLOOM GREGORY
IPC分类号： G01N33/53 , C12M1/00
CPC分类号： G01N33/57419 , G01N2800/60
摘要： Methods and systems are described for using in making a diagnosis of colorectal cancer in a subject. A method can include providing a biological sample from the subject; determining an amount in the sample of at least one peptide marker, selected from a group of markers as described herein; and comparing the amount of the at least one peptide marker in the sample, if present, to a control level of the at least one peptide marker, wherein the subject is diagnosed as having colorectal cancer or a risk thereof if there is a measurable difference in the amount of the at least one peptide marker in the sample as compared to the control level.
摘要翻译：描述了用于在受试者中诊断结肠直肠癌的方法和系统。方法可以包括从受试者提供生物样品; 确定样品中至少一种选自如本文所述的标记物组中的肽标记物的量; 以及将所述样品中至少一种肽标记物的量（如果存在）与所述至少一种肽标记物的对照水平进行比较，其中所述受试者被诊断为具有结肠直肠癌或其风险，如果存在可测量的差异与对照水平相比，样品中至少一个肽标记物的量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式